Acute Lymphocytic/Lymphoblastic Leukemia Market - Forecast(2021 - 2026)

Report Code: HCR 27583 Report Format: PDF + Excel (Delivery in 48 Hrs)

Acute Lymphocytic/Lymphoblastic Leukemia Market Overview

Acute Lymphocytic/Lymphoblastic Leukemia Market size is estimated to reach $3.23Bn by 2025, growing at a CAGR of 5.1% during the forecast period 2020-2025. Acute Lymphocytic/Lymphoblastic Leukemia is a type of cancer of blood and bone marrow that affects white blood cells. It occurs when a bone marrow cell develops errors in its DNA. It is the most common childhood cancer. Advancements in technology for detecting affected cells, increasing awareness about early diagnosis in the developing countries, growing demand for improved Cancer therapies and increase in the focus towards addressing the unmet medical needs are the factors that are set to drive the growth of the global market for the forecast period 2020-2025.

Acute Lymphocytic/Lymphoblastic Leukemia Market Report Coverage

The report: “Acute Lymphocytic/Lymphoblastic Leukemia Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Acute Lymphocytic/Lymphoblastic Leukemia Market. 
By Type: B-Cell ALL, T-Cell ALL and Philadelphia Chromosome.
By Therapy: Chemotherapy, Targeted Therapy, Radiation Therapy and Stem Cell Transplant.
By Geography: North America, Asia-Pacific, Europe, Rest of World (RoW).

Key Takeaways

  • Geographically, North America Acute Lymphocytic/Lymphoblastic Leukemia Market accounted for the highest revenue share in 2019 and it is poised to dominate during the forecast period 2020-2025 owing to the high demand.
  • Rise in the number of bone marrow biopsies and increase in the research and development activities is likely to aid in the market growth of Acute Lymphocytic/Lymphoblastic Leukemia Market.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Acute Lymphocytic/Lymphoblastic Leukemia Market report.
  • The growing demand for targeted therapies and growing focus towards addressing the unmet needs are creating higher opportunities for the growth of market for the forecast period 2020-2025.

Acute Lymphocytic/Lymphoblastic Leukemia Market Segment Analysis - By Type 

Based on the Type, B-Cell ALL segment held the largest share in 2019 owing to the factors such as high development in the early stages, rise in the prevalence in the adults who have had certain types of chemotherapy and radiation therapy, exposure to high doses of X-rays and other forms of radiation.

Acute Lymphocytic/Lymphoblastic Leukemia Market Segment Analysis - By Therapy

Based on the Therapy, Chemotherapy segment held the largest share in 2019 owing to the factors such as it has the ability to destroy leukemia cells and prevents thriving and multiplication of cancerous cells that impede the progress of the disease. Stem cell transplant can also be used with chemotherapy, which helps the healthcare practitioners induce chemotherapy infusions for effective treatment.

Acute Lymphocytic/Lymphoblastic Leukemia Market Segment Analysis - By Geography 

Based on the Geography, North America held the largest share in 2019. The growth in this segment is owing to the factors such as easy availability of treatments, presence of key players in the developed nations, increase in the government initiatives and advancements in technology for detecting the affected cells. Asia-Pacific is estimated to be the fastest growing segment owing to the factors such as growing awareness about the importance of early diagnosis in the emerging countries like India and China and increase in the awareness of targeted therapies.

Acute Lymphocytic/Lymphoblastic Leukemia Market Drivers

Increase in the awareness about the importance of early diagnosis and rise in the incidence of cancer cases

The increase in the awareness about the importance of early diagnosis is estimated to enhance the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market. Rise in the incidence of cancer cases is also said to enhance the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market.

Increase in the government initiatives and growing demand for improved cancer therapies

There is an increase in the government initiatives owing to increase in the burden of cancer among geriatric population. This led to rapid increase in the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market. Increase in the demand for cancer therapies is also estimated to enhance the growth of the Acute Lymphocytic/Lymphoblastic Leukemia Market.

Acute Lymphocytic/Lymphoblastic Leukemia Market Challenges

The stringent regulatory approvals for the therapeutics and higher costs associated with the therapies

The stringent regulatory approvals for the therapeutics is said to reduce the growth of the Acute Lymphocytic/Lymphoblastic Leukemia Market. Patent expiry of antineoplastic drugs and higher costs associated with the therapies are also the factors, which are estimated to reduce the growth of Acute Lymphocytic/Lymphoblastic Leukemia Market.

Acute Lymphocytic/Lymphoblastic Leukemia Industry outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Acute Lymphocytic/Lymphoblastic Leukemia Market. Key companies of this market are GlaxoSmithKline Plc, Pfizer Inc, Genzyme Corporation, Erytech Pharma, Novartis AG, Celgene Corporation, Dr. Reddys Laboratories Ltd, Spectrum Pharmaceuticals Inc, Sanofi, Leadiant Biosciences Inc among others.

Acquisitions/Product Launches:

  • In 2018, ERYTECH Pharma has launched eryaspase, also known by the trade name GRASPA, for patients with acute lymphoblastic leukemia (ALL).
  • In 2016, Celgene Corporation has entered into an agreement with Juno Therapeutics Inc to develop and commercialize the Juno CD19 for benefitting the patients with acute lymphoblastic leukemia (ALL).
  • In 2017, Dr. Reddys Laboratories Ltd has launched Clofarabine Injection, a therapeutic equivalent generic version of clolar injection, which is used to treat acute lymphoblastic leukemia (ALL).

1. Acute Lymphocytic/Lymphoblastic Leukemia Market - Overview
    1.1 Definitions and Scope
2. Acute Lymphocytic/Lymphoblastic Leukemia Market - Executive Summary
    2.1 Market Revenue, Market Size and Key Trends
    2.2 Key trends by Type
    2.3 Key trends by Therapy
    2.4 Key trends by Geography
3. Acute Lymphocytic/Lymphoblastic Leukemia Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies 
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Acute Lymphocytic/Lymphoblastic Leukemia Market - Startup Companies Scenario Premium
4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Acute Lymphocytic/Lymphoblastic Leukemia Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Acute Lymphocytic/Lymphoblastic Leukemia - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Acute Lymphocytic/Lymphoblastic Leukemia Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Acute Lymphocytic/Lymphoblastic Leukemia Market – By Type (Market Size –$Million/$Billion)
    8.1 B-Cell ALL
    8.2 T-Cell ALL
    8.3 Philadelphia Chromosome
9. Acute Lymphocytic/Lymphoblastic Leukemia Market – By Therapy (Market Size –$Million/$Billion)
    9.1 Chemotherapy
    9.2 Targeted Therapy
    9.3 Radiation Therapy
    9.4 Stem Cell Therapy
    9.5 Others
10. Acute Lymphocytic/Lymphoblastic Leukemia Market - By Geography (Market Size –$Million/$Billion)
    10.1 North America
        10.1.1 U.S.
        10.1.2 Canada
        10.1.3 Mexico
    10.2 Europe
        10.2.1 U.K.
        10.2.2 Germany
        10.2.3 France
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Rest of Europe
    10.3 Asia-Pacific
        10.3.1 China
        10.3.2 India
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 Australia & New Zealand
        10.3.6 Rest of Asia-Pacific
        10.4 Rest of the World
        10.4.1 Middle East
        10.4.2 Africa
        10.4.3 South America
11. Acute Lymphocytic/Lymphoblastic Leukemia Market - Entropy
12. Acute Lymphocytic/Lymphoblastic Leukemia Market – Industry/Segment Competition Landscape Premium 
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key companies
        12.1.3 Market Share by Countries – Key Companies
        12.1.4 Best Practices for Companies
13. Acute Lymphocytic/Lymphoblastic Leukemia Market – Key Company List by Country Premium Premium
14. Acute Lymphocytic/Lymphoblastic Leukemia Market Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2019-2024 ($M)
1.1 Pediatric Market 2019-2024 ($M) - Global Industry Research
1.2 Adult Market 2019-2024 ($M) - Global Industry Research
2.Global ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2019-2024 ($M)
2.1 Overvie Market 2019-2024 ($M) - Global Industry Research
2.2 Hyper-CVAD regimen Market 2019-2024 ($M) - Global Industry Research
2.3 Linker regimen Market 2019-2024 ($M) - Global Industry Research
2.4 Nucleoside metabolic inhibitors Market 2019-2024 ($M) - Global Industry Research
2.6 CALGB 8811 regimen Market 2019-2024 ($M) - Global Industry Research
2.7 Oncaspar Market 2019-2024 ($M) - Global Industry Research
3.Global ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2019-2024 (Volume/Units)
3.1 Pediatric Market 2019-2024 (Volume/Units) - Global Industry Research
3.2 Adult Market 2019-2024 (Volume/Units) - Global Industry Research
4.Global ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2019-2024 (Volume/Units)
4.1 Overvie Market 2019-2024 (Volume/Units) - Global Industry Research
4.2 Hyper-CVAD regimen Market 2019-2024 (Volume/Units) - Global Industry Research
4.3 Linker regimen Market 2019-2024 (Volume/Units) - Global Industry Research
4.4 Nucleoside metabolic inhibitors Market 2019-2024 (Volume/Units) - Global Industry Research
4.6 CALGB 8811 regimen Market 2019-2024 (Volume/Units) - Global Industry Research
4.7 Oncaspar Market 2019-2024 (Volume/Units) - Global Industry Research
5.North America ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2019-2024 ($M)
5.1 Pediatric Market 2019-2024 ($M) - Regional Industry Research
5.2 Adult Market 2019-2024 ($M) - Regional Industry Research
6.North America ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2019-2024 ($M)
6.1 Overvie Market 2019-2024 ($M) - Regional Industry Research
6.2 Hyper-CVAD regimen Market 2019-2024 ($M) - Regional Industry Research
6.3 Linker regimen Market 2019-2024 ($M) - Regional Industry Research
6.4 Nucleoside metabolic inhibitors Market 2019-2024 ($M) - Regional Industry Research
6.6 CALGB 8811 regimen Market 2019-2024 ($M) - Regional Industry Research
6.7 Oncaspar Market 2019-2024 ($M) - Regional Industry Research
7.South America ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2019-2024 ($M)
7.1 Pediatric Market 2019-2024 ($M) - Regional Industry Research
7.2 Adult Market 2019-2024 ($M) - Regional Industry Research
8.South America ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2019-2024 ($M)
8.1 Overvie Market 2019-2024 ($M) - Regional Industry Research
8.2 Hyper-CVAD regimen Market 2019-2024 ($M) - Regional Industry Research
8.3 Linker regimen Market 2019-2024 ($M) - Regional Industry Research
8.4 Nucleoside metabolic inhibitors Market 2019-2024 ($M) - Regional Industry Research
8.6 CALGB 8811 regimen Market 2019-2024 ($M) - Regional Industry Research
8.7 Oncaspar Market 2019-2024 ($M) - Regional Industry Research
9.Europe ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2019-2024 ($M)
9.1 Pediatric Market 2019-2024 ($M) - Regional Industry Research
9.2 Adult Market 2019-2024 ($M) - Regional Industry Research
10.Europe ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2019-2024 ($M)
10.1 Overvie Market 2019-2024 ($M) - Regional Industry Research
10.2 Hyper-CVAD regimen Market 2019-2024 ($M) - Regional Industry Research
10.3 Linker regimen Market 2019-2024 ($M) - Regional Industry Research
10.4 Nucleoside metabolic inhibitors Market 2019-2024 ($M) - Regional Industry Research
10.6 CALGB 8811 regimen Market 2019-2024 ($M) - Regional Industry Research
10.7 Oncaspar Market 2019-2024 ($M) - Regional Industry Research
11.APAC ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2019-2024 ($M)
11.1 Pediatric Market 2019-2024 ($M) - Regional Industry Research
11.2 Adult Market 2019-2024 ($M) - Regional Industry Research
12.APAC ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2019-2024 ($M)
12.1 Overvie Market 2019-2024 ($M) - Regional Industry Research
12.2 Hyper-CVAD regimen Market 2019-2024 ($M) - Regional Industry Research
12.3 Linker regimen Market 2019-2024 ($M) - Regional Industry Research
12.4 Nucleoside metabolic inhibitors Market 2019-2024 ($M) - Regional Industry Research
12.6 CALGB 8811 regimen Market 2019-2024 ($M) - Regional Industry Research
12.7 Oncaspar Market 2019-2024 ($M) - Regional Industry Research
13.MENA ACUTE LYMPHOCYTIC LEUKEMIA MARKET, BY TYPE Market 2019-2024 ($M)
13.1 Pediatric Market 2019-2024 ($M) - Regional Industry Research
13.2 Adult Market 2019-2024 ($M) - Regional Industry Research
14.MENA ACUTE LYMPHOCYTIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG Market 2019-2024 ($M)
14.1 Overvie Market 2019-2024 ($M) - Regional Industry Research
14.2 Hyper-CVAD regimen Market 2019-2024 ($M) - Regional Industry Research
14.3 Linker regimen Market 2019-2024 ($M) - Regional Industry Research
14.4 Nucleoside metabolic inhibitors Market 2019-2024 ($M) - Regional Industry Research
14.6 CALGB 8811 regimen Market 2019-2024 ($M) - Regional Industry Research
14.7 Oncaspar Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
2.Canada Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
3.Mexico Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
4.Brazil Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
5.Argentina Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
6.Peru Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
7.Colombia Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
8.Chile Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
9.Rest of South America Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
10.UK Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
11.Germany Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
12.France Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
13.Italy Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
14.Spain Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
15.Rest of Europe Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
16.China Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
17.India Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
18.Japan Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
19.South Korea Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
20.South Africa Acute Lymphocytic/Lymphoblastic Leukemia Market Revenue, 2019-2024 ($M)
21.North America Acute Lymphocytic/Lymphoblastic Leukemia By Application
22.South America Acute Lymphocytic/Lymphoblastic Leukemia By Application
23.Europe Acute Lymphocytic/Lymphoblastic Leukemia By Application
24.APAC Acute Lymphocytic/Lymphoblastic Leukemia By Application
25.MENA Acute Lymphocytic/Lymphoblastic Leukemia By Application
26.AMGEN, INC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.BRISTOL-MYERS SQUIBB COMPANY, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.ERYTECH PHARMA, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.LEADIANT BIOSCIENCES, INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.NOVARTIS AG, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.PFIZER, INC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.RARE DISEASE THERAPEUTICS, INC., Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.SANOFI, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.SPECTRUM PHARMACEUTICALS, INC, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.TAKEDA PHARMACEUTICAL COMPANY LIMITED, Sales /Revenue, 2015-2018 ($Mn/$Bn)